Attached files
| file | filename |
|---|---|
| EX-99.1 - IDENIX PHARMACEUTICALS INC | v179126_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
report (Date of earliest event reported): March 30, 2010
IDENIX
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-49839
|
45-0478605
|
|
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
60
Hampshire Street
Cambridge,
MA
|
02139
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(617) 995-9800
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02
|
Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers
|
(d)
On March
30, 2010, upon recommendation of the Nominating and Corporate Governance
Committee of the Board of Directors of Idenix Pharmaceuticals, Inc. (the
“Company”), the Board of Directors of the Company (the “Board”) elected Tamar D.
Howson to the Board. Ms. Howson is currently a Partner with
JSB-Partners, a transaction advisory firm serving the life sciences industry,
and has been a senior corporate and business development associate at several
large pharmaceutical companies, including Bristol Myers Squibb and SmithKline
Beecham.
Ms.
Howson will be entitled to cash and equity compensation for her services on the
Board in accordance with the Company’s director compensation policies, as
described under the heading “Director Compensation” in the proxy statement for
our 2009 annual meeting of stockholders, as filed with the Securities and
Exchange Commission on April 28, 2009.
On March
30, 2010, the Company issued a press release announcing the election of Ms.
Howson to the Board. The full text of the press release issued in
connection with this announcement is attached as Exhibit 99.1 and incorporated
by reference herein.
|
Item
9.01
|
Financial
Statements and Exhibits
|
(d)
Exhibits
99.1 Press
release, dated March 30, 2010, issued by Idenix Pharmaceuticals,
Inc.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, as amended, the Registrant has duly caused this
report to be signed by the undersigned hereunto duly authorized.
|
IDENIX
PHARMACEUTICALS, INC.
|
||
|
Date: March
30, 2010
|
By:
|
/s/ Ronald C. Renaud,
Jr.
|
|
Ronald
C. Renaud, Jr.
|
||
|
Chief
Financial Officer and Treasurer
|
||
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
release, dated March 30, 2010, issued by Idenix Pharmaceuticals,
Inc.
|